Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMGN Amgen

Closed 05-02 16:00:00 EDT

278.39

+1.02

+0.37%

盘后319.00

+40.61+14.59%

19:59 EDT

High278.63	Low274.90	Vol3.18M
Open277.69	D1 Closing277.37	Amplitude1.34%
Mkt Cap149.32B	Tradable Cap148.89B	Total Shares536.38M
T/O881.17M	T/O Rate0.59%	Tradable Shares534.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"Amgen","latestPrice":278.39,"timestamp":1714680000000,"preClose":277.37,"halted":0,"volume":3177473,"hourTrading":{"tag":"盘后","latestPrice":318.9999,"preClose":278.39,"latestTime":"19:59 EDT","volume":616848,"amount":187443933.8994,"timestamp":1714694398635},"delay":0,"floatShares":534807507,"shares":536375548,"eps":12.49,"marketStatus":"Closed","change":1.02,"latestTime":"05-02 16:00:00 EDT","open":277.69,"high":278.63,"low":274.9,"amount":881168995.77642,"amplitude":0.013448,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":12.49,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1714723200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":277.37,"dividendRate":0.030605,"preHourTrading":{"tag":"盘前","latestPrice":279,"preClose":277.37,"latestTime":"09:21 EDT","volume":993,"amount":276457.83324,"timestamp":1714656100788},"postHourTrading":{"tag":"盘后","latestPrice":318.9999,"preClose":278.39,"latestTime":"19:59 EDT","volume":616848,"amount":187443933.8994,"timestamp":1714694398635},"volumeRatio":1.356592,"optionData":{"bulkOrders":[{"symbol":"AMGN","call":false,"expireDate":1718942400000,"strike":"235.0","timestamp":1714660015819,"price":1.09,"volume":2250,"amount":245250,"type":"-"}]}},"requestUrl":"/m/hq/s/AMGN/tweets","defaultTab":"tweets","newsList":[{"id":"1159876149","title":"Amgen \"Encouraged\" By Weight-Loss Drug Interim Data, Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=1159876149","media":"Reuters","top":1,"share":"https://ttm.financial/m/news/1159876149?lang=en_us&edition=fundamental","pubTime":"2024-05-03 06:30","pubTimestamp":1714689000,"startTime":"0","endTime":"0","summary":"May 2 (Reuters) - Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide and will no longer develop its ora","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"c0d77e622a6742cf8335299f8317b4b4","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2432653829","title":"BUZZ-Amgen climbs on optimism over interim mid-stage trial data for weight-loss drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2432653829","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432653829?lang=en_us&edition=fundamental","pubTime":"2024-05-03 06:33","pubTimestamp":1714689196,"startTime":"0","endTime":"0","summary":"(Updates)   ** Drugmaker Amgen's    shares reverse losses, climb 13.2% to $315 in extended trading         ** Company    says    it was encouraged by findings after completing a mid-stage study's inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432964693","title":"Here's What Key Metrics Tell Us About Amgen (AMGN) Q1 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2432964693","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432964693?lang=en_us&edition=fundamental","pubTime":"2024-05-03 06:00","pubTimestamp":1714687207,"startTime":"0","endTime":"0","summary":"For the quarter ended March 2024, Amgen  reported revenue of $7.45 billion, up 22% over the same period last year. EPS came in at $3.96, compared to $3.98 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $7.38 billion, representing a surprise of +0.93%. The company delivered an EPS surprise of +5.32%, with the consensus EPS estimate being $3.76.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Product Sales- EPOGEN- US: $41 million compared to the $47.52 million average estimate based on nine analysts. The reported number represents a change ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xMhOxlfdhVA7Ts3pP3IHyA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xMhOxlfdhVA7Ts3pP3IHyA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-key-metrics-tell-us-220007876.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432950563","title":"Amgen shares rally as drugmaker expects weight-loss drug trial data this year","url":"https://stock-news.laohu8.com/highlight/detail?id=2432950563","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432950563?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:49","pubTimestamp":1714686540,"startTime":"0","endTime":"0","summary":"This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432950880","title":"Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2432950880","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432950880?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:44","pubTimestamp":1714686280,"startTime":"0","endTime":"0","summary":"Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses driven by the Horizon acquisition, partially offset by higher revenues.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/05/38601856/amgen-reports-better-than-expected-q1-results-50m-milestone-payment","is_publish_highlight":false,"gpt_icon":0},{"id":"2432968478","title":"Amgen Inc (AMGN) Q1 2024 Earnings: Aligns with EPS Projections Amid Revenue Growth and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2432968478","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2432968478?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:42","pubTimestamp":1714686152,"startTime":"0","endTime":"0","summary":"Revenue: $7.4 billion, up 22% year-over-year, surpassing estimates of $7.435 billion.Net Income: Reported a net loss of $113 million, a significant drop from a net income of $2.841 billion in Q1 2023, below estimates of $2.088 billion.Earnings Per Share : GAAP loss per share was $0.21, compared to earnings of $5.28 in Q1 2023, below the estimated earnings per share of $3.87.Free Cash Flow: Generated $0.5 billion, down from $0.7 billion in the same quarter last year.Operating Margin: GAAP operating margin decreased significantly by 19.0 percentage points to 13.9%.Product Sales: Total product sales increased by 22%, driven by volume growth of 25%, with significant contributions from Horizon-acquired products.Dividends: Paid a dividend of $2.25 per share, representing a 6% increase from the previous year.On May 2, 2024, Amgen Inc  disclosed its financial results for the first quarter of 2024 through its 8-K filing. The company reported a significant revenue increase but faced challenges w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-inc-amgn-q1-2024-214232247.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432895706","title":"Amgen stock rallies 13% on weight-loss drug updates, tweaked guidanace","url":"https://stock-news.laohu8.com/highlight/detail?id=2432895706","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432895706?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:40","pubTimestamp":1714686021,"startTime":"0","endTime":"0","summary":"Shares of Amgen rallied 13% in post-market trading Thursday after the biotech giant issued its Q1 earnings report, tweaked its 2024 guidance and offered an update on its weight-loss drug candidates. A","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099298-amgen-stock-rallies-on-weight-loss-drug-updates-tweaked-guidanace","is_publish_highlight":false,"gpt_icon":0},{"id":"2432968470","title":"Amgen Soars After CEO Gives Update on Experimental Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2432968470","media":"Bloomberg","top":-1,"share":"https://ttm.financial/m/news/2432968470?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:29","pubTimestamp":1714685366,"startTime":"0","endTime":"0","summary":" -- Amgen Inc.’s shares soared in late trading after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide.Saudi Arabia Steps Up Arrests Of Those Attacking Israel Online. Huawei Secretly Backs US Research, Awarding Millions in Prizes. Biden Calls Ally Japan ‘Xenophobic’ Along With China, Russia. Turkey Confirms All Trade Halt With Israel Over War in Gaza. US and Saudis Near Defense Pact Meant to Reshape Middle East. “We recognize the significant interest in obesity,” Amgen CEO Robert Bradway said Thursday on a call with investors. “We are confident in MariTide’s differentiated profile and believe it will address important unmet medical needs.”Amgen shares rose as much as 12% after US markets closed. If the gain holds into Friday’s regular trading, Amgen will be set for its biggest intraday increase since 2009.Why Banks These Days Are So Excited About Being Boring","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/thXvFp713tj0DGBRV6qziA--~B/aD0xMzMzO3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_markets_842/a02fc587493da7693372b39207cb73d1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/thXvFp713tj0DGBRV6qziA--~B/aD0xMzMzO3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_markets_842/a02fc587493da7693372b39207cb73d1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-soars-ceo-gives-experimental-212926077.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432527749","title":"Amgen expects data from weight-loss drug trial later this year","url":"https://stock-news.laohu8.com/highlight/detail?id=2432527749","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432527749?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:21","pubTimestamp":1714684860,"startTime":"0","endTime":"0","summary":"Shares of Amgen Inc. rallied more than 11% in the extended session Thursday after the drugmaker posted adjusted earnings above expectations and said that plans for further trials for its weight-loss drug are proceeding apace.Amgen said that it expects data from an ongoing phase 2 study of MariTide, an injectable weight-loss drug, late in the year. The drugmaker said that plans for a \"comprehensive\" phase 3 program remain on track.Amgen  lost $113 million, or 21 cents a share, in the quarter, contrasting with earnings of $2.8 billion, or $5.28 a share, in the first quarter of 2023.It pinned the loss on higher operating expenses, including those related to its acquisition of Horizon Therapeutics. The acquisition, which ran against regulatory hurdles, was completed in October.Adjusted for one-time items, Amgen earned $3.96 a share, above expectations of $3.88 a share, according to FactSet.The drugmaker's revenue rose 22% to $7.45 billion, meeting the FactSet consensus. Product sales were ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432955963","title":"BUZZ-Amgen down after quarterly profit dips 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432955963","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432955963?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:20","pubTimestamp":1714681238,"startTime":"0","endTime":"0","summary":"** Shares of Amgen    down 2.3% to $272 in trading after the bell   ** Co posted slightly lower Q1 profit on higher operating and interest expenses from its recent acquisition of rare disease drugmaker Horizon Therapeutics   ** Its adj per-share profit fell 1% to $3.96, which still beat the average analyst estimate of $3.88/share, as per LSEG data   ** AMGN nudged up the lower end of its annual rev outlook to between $32.5 bln and $33.8 bln from a previous view of $32.4 bln to $33.8 bln   ** Co also narrowed its 2024 adj. per-share earnings estimate and now sees a profit of $19.00 to $20.20/share from a previous view of $18.90 to $20.30   ** As of the last close, stock down 3.3% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432195590","title":"Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2432195590","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432195590?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:17","pubTimestamp":1714681034,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals  said on Thursday it had received a $50M milestone payment from Royalty Pharma . Shares of ARWR rose 1.5% in extended trading. The milestone was triggered after the completion of enrollment of the Phase 3 OCEAN - Outcomes Trial of olpasiran, being conducted by Amgen .  Pursuant to its 2016 agreement with AMGN and 2022 agreement with RPRX, ARWR is further eligible to receive up to an additional $375M from AMGN and $110M from RPRX in aggregate development, regulatory, and sales milestone payments associated with olpasiran. Press Release","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099116-arrowhead-pharmaceuticals-secures-50m-milestone-from-royalty-pharma","is_publish_highlight":false,"gpt_icon":0},{"id":"2432720953","title":"Amgen Non-GAAP EPS of $3.96 beats by $0.05, revenue of $7.45B in-line","url":"https://stock-news.laohu8.com/highlight/detail?id=2432720953","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432720953?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:03","pubTimestamp":1714680224,"startTime":"0","endTime":"0","summary":"Amgen press release  : Q1  Non-GAAP EPS of $3.96  beats by $0.05.FY24 revenue consensus of $32.95B, EPS consensus of $19.53","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099057-amgen-non-gaap-eps-of-3_96-beats-0_05-revenue-of-7_45b-in-line","is_publish_highlight":false,"gpt_icon":0},{"id":"2432975951","title":"Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2432975951","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432975951?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:01","pubTimestamp":1714680060,"startTime":"0","endTime":"0","summary":"PASADENA, Calif., May 02, 2024----Arrowhead Pharmaceuticals, Inc.  today announced a $50 million milestone payment was received from Royalty Pharma plc . This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN - Outcomes Trial of olpasiran, being conducted by Amgen . Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sales milestone payments associated with olpasiran.Olpasiran is a small interfering RNA  originally developed by Arrowhead using its proprietary Targeted RNAi Molecule  platform. It is designed to lower levels of lipoprotein , a genetically determined risk factor for cardiovascular disease. The primary objective of the Phase 3 OCEAN - Outcomes Trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bvoFKuFr5RUvD_zQYPKbgg--~B/aD0zMzU7dz0xNjA5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f0b0c75fe13f036d700237031b287f61","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bvoFKuFr5RUvD_zQYPKbgg--~B/aD0zMzU7dz0xNjA5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f0b0c75fe13f036d700237031b287f61"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-earns-50-million-200100226.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432953058","title":"AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2432953058","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2432953058?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:01","pubTimestamp":1714680060,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 2, 2024 /PRNewswire/ -- Amgen  today announced financial results for the first quarter 2024.\"With many of our innovative products delivering strong growth and promising new medicines advancing through our pipeline, we are excited about delivering attractive long-term growth,\" said Robert A.Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 22% to $7.4 billion in comparison to the first quarter of 2023. Product sales grew 22%, driven by 25% volume growth.Ten products delivered at least double-digit volume growth in the first quarter, includingRepatha , TEZSPIRE , EVENITY , BLINCYTO , and TAVNEOS .U.S. volume grew 29% and ex-U.S. volume grew 17%.GAAP loss per share was $0.21 for the first quarter of 2024 compared with GAAP earnings per share  of $5.28 for the first quarter of 2023, driven by a mark-to-market loss on our BeiGene, Ltd. equity investment and higher operating expenses, including higher amortization expense","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MUwJUMkfdcxSbG3aWkeckA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MUwJUMkfdcxSbG3aWkeckA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2024-200100451.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2024-200100451.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432091937","title":"CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling","url":"https://stock-news.laohu8.com/highlight/detail?id=2432091937","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432091937?lang=en_us&edition=fundamental","pubTime":"2024-05-03 03:32","pubTimestamp":1714678325,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics, Inc. results from phase 1a dose-escalation study, using CX-904 for the treatment of patients with EGFR expressing solid tumors, expected with Q1 2024 earnings on May 8, 2024.Pendi","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1997149240/image_1997149240.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1997149240/image_1997149240.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688677-cytomx-cx-904-tumor-treatment-data-might-get-ball-rolling","is_publish_highlight":false,"gpt_icon":0},{"id":"2432593434","title":"S&P 500, Nasdaq Rise Intraday Amid Moderna Rally as Traders Await Apple Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2432593434","media":"MT Newswires","top":-1,"share":"https://ttm.financial/m/news/2432593434?lang=en_us&edition=fundamental","pubTime":"2024-05-03 02:23","pubTimestamp":1714674181,"startTime":"0","endTime":"0","summary":"The S&P 500 and the Nasdaq Composite were higher intraday, buoyed by a post-earnings rally in Moderna's  stock, as investors awaited Apple's  results.The technology-heavy Nasdaq was up 1.2% at 15,793.7 after midday Thursday, while the S&P 500 rose 0.7% to 5,054.3. The Dow Jones Industrial Average advanced 0.6% to 38,163.3. Among sectors, consumer discretionary and tech led the gainers. Only materials and healthcare were in the red.In company news, Moderna shares jumped 12%, the best performer on the Nasdaq and among the best on the S&P 500. The drugmaker logged a smaller-than-expected loss for the first quarter and affirmed its full-year revenue outlook.C.H. Robinson Worldwide  was the top gainer on the S&P 500, up 16%. The company late Wednesday delivered a first-quarter beat.DoorDash  shares tumbled 11%, the steepest decline on the Nasdaq. The food delivery company late Wednesday recorded a slightly wider-than-expected first-quarter loss, while its short-term core profit outlook fell","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_8ROLj_eGdOJIxXAZcVMog--~B/aD03Njg7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_8ROLj_eGdOJIxXAZcVMog--~B/aD03Njg7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/p-500-nasdaq-rise-intraday-182301570.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2432493301","title":"BUZZ-PREVIEW: Amgen slips ahead of Q1 earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2432493301","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432493301?lang=en_us&edition=fundamental","pubTime":"2024-05-03 01:38","pubTimestamp":1714671517,"startTime":"0","endTime":"0","summary":"** Amgen    shares down 0.8% at $275.05 ahead of Q1 results due after the closing bell    ** The biotech company is expected to post EPS of $3.87 on revenue $7.44 bln, per LSEG data, vs yr-ago results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432675120","title":"Options Volatility and Implied Earnings Moves Today, May 02, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432675120","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432675120?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:05","pubTimestamp":1714647942,"startTime":"0","endTime":"0","summary":"Today, several major companies are expected to report earnings: Amgen (AMGN), Apple (AAPL), Conocophillips (COP), Mercadolibre (MELI), Block (SQ), ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/options-volatility-and-implied-earnings-moves-today-may-02-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/options-volatility-and-implied-earnings-moves-today-may-02-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432867310","title":"Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2432867310","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432867310?lang=en_us&edition=fundamental","pubTime":"2024-05-02 18:52","pubTimestamp":1714647171,"startTime":"0","endTime":"0","summary":"U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38576979/nasdaq-s-p-500-futures-rise-ahead-of-apple-earnings-why-this-analyst-thinks-no-cut-scenario-may-not","is_publish_highlight":false,"gpt_icon":1},{"id":"2432596186","title":"Notable earnings after Thursday's close","url":"https://stock-news.laohu8.com/highlight/detail?id=2432596186","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432596186?lang=en_us&edition=fundamental","pubTime":"2024-05-02 05:35","pubTimestamp":1714599320,"startTime":"0","endTime":"0","summary":"Major earnings expected after the bell on Thursday include:  Apple  Block  Amgen  Coinbase Global  DraftKings   Other earnings slated for release after Thursday's close include:   AAON, ACA, ACCO, AEE, AES, ALG, ALTR, AMH, ARDX, ASND, ASUR, ATGE, ATRO, AXTI, BBAI, BECN, BFAM, BILL, BJRI, BKNG, BOOM, CABO, CDXS, CERS, CIVI, CLAR, CLFD, COHU, CPT, CRDF, CSTL, CTHR, CTO, CTRA, CTRE, DLB, DLR, DMRC, DRH, DVA, EB, ED, EOG, EVC, EXPE, FDP, FDUS, FIVN, FND, FOXF, FRT, FTNT, GAU, GDDY, GEVO, GLPG, GSIT, HOLX, HTGC, HUN, ILMN, IR, IRTC, JYNT, KRC, KURA, KWR, LASR, LFVN, LMAT, LNT, LOCO, LXRX, LYV, MATW, MELI, MNST, MP, MRIN, MSI, MTZ, MX, NR, OFS, OHI, OLED, OPEN, OSPN, OTEX, OUT, PBYI, PCTY, PLMR, POST, PTVE, PXD, RARE, REG, REZI, RGA, RKT, RMAX, SAND, SEM, SES, SIMO, SM, SPT, SPXC, STEM, SWN, TDW, TNDM, TPIC, OTCPK:TRRSF, TRUP, TWOU, TWST, TXRH, UDMY, UMH, UPLD, VIAV, VIR, VREX, VRRM, WK, WSC, WTRG, WW, X, XHR, XPOF, ZEUS, ZYME  For Seeking Alpha's full earnings season calendar, click here.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4097359-notable-earnings-after-thursdays-close","is_publish_highlight":false,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.1454},{"period":"6month","weight":0.0278},{"period":"1year","weight":0.1754},{"period":"ytd","weight":-0.037}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.","yearOnYearQuotes":[{"month":1,"riseRate":0.634146,"avgChangeRate":0.032606},{"month":2,"riseRate":0.463415,"avgChangeRate":-0.003118},{"month":3,"riseRate":0.512195,"avgChangeRate":0.019417},{"month":4,"riseRate":0.463415,"avgChangeRate":-0.001307},{"month":5,"riseRate":0.536585,"avgChangeRate":0.022463},{"month":6,"riseRate":0.5,"avgChangeRate":0.004307},{"month":7,"riseRate":0.756098,"avgChangeRate":0.052175},{"month":8,"riseRate":0.609756,"avgChangeRate":0.00518},{"month":9,"riseRate":0.536585,"avgChangeRate":0.003724},{"month":10,"riseRate":0.536585,"avgChangeRate":0.021341},{"month":11,"riseRate":0.634146,"avgChangeRate":0.022436},{"month":12,"riseRate":0.658537,"avgChangeRate":0.050861}],"exchange":"NASDAQ","name":"Amgen","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amgen(AMGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amgen,AMGN,Amgen股票,Amgen股票老虎,Amgen股票老虎国际,Amgen行情,Amgen股票行情,Amgen股价,Amgen股市,Amgen股票价格,Amgen股票交易,Amgen股票购买,Amgen股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amgen(AMGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amgen(AMGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction